Clinical Trial: F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07829614) titled 'F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus' on Sept. 02.

Brief Summary: The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA. Through a dual-targeting mechanism, it aims to guide the body's own immune system to target and kill B cells and plasma cells that overexpress BCMA.Based on the application of B cell depletion strategies in the treatment of autoimmune diseases, as well as the exploration of similar drugs in autoimmune disease...